Non Hodgkin Lymphoma Clinical Trial

Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells

Summary

This protocol is designed as a long-term follow-up study of participants who will receive genetically modified autologous CAR-T cells as part of clinical trial at the Medical College of Wisconsin/ Froedtert Hospital-- Phase 1 Study of CAR-20/19-T Cells in Patients with Relapsed Refractory B Cell Malignancies (NCT03019055).

View Full Description

Full Description

The objective is to follow participants receiving cluster of differentiation (CD) 20 / cluster of differentiation (CD) 19 lentiviral modified CAR-T cells (CAR-20/19-T cells) from years 2 to 15 post-treatment for persistence of CAR-T cells, development of secondary malignancies, or other medical complications.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

All participants who enrolled in the Phase 1 CAR-20/19-T cell study at Froedtert & the Medical College of Wisconsin.

Exclusion Criteria:

There are no exclusion criteria for this study.

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

24

Study ID:

NCT03375619

Recruitment Status:

Recruiting

Sponsor:

Medical College of Wisconsin

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Froedtert Hospital & Medical College of Wisconsin
Milwaukee Wisconsin, 53226, United States More Info
Cancer Center Clinical Trials Office
Contact
414-805-8900
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Estimated Enrollment:

24

Study ID:

NCT03375619

Recruitment Status:

Recruiting

Sponsor:


Medical College of Wisconsin

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.